http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Choi, Eue-Keun,Shen, Mark J.,Lin, Shien-Fong,Chen, Peng-Sheng,Oh, Seil WB SAUNDERS CO LTD 2014 EUROPACE -LONDON- Vol.16 No.7
<P><B>Aims</B></P><P>We hypothesized that carvedilol can effectively suppress autonomic nerve activity (ANA) in ambulatory dogs during sinus rhythm and atrial fibrillation (AF), and that carvedilol withdrawal can lead to rebound elevation of ANA. Carvedilol is known to block pre-junctional β2-adrenoceptor responsible for norepinephrine release.</P><P><B>Methods and results</B></P><P>We implanted radiotransmitters to record stellate ganglion nerve activity (SGNA), vagal nerve activity (VNA), and superior left ganglionated plexi nerve activity (SLGPNA) in 12 ambulatory dogs. Carvedilol (12.5 mg orally twice a day) was given for 7 days during sinus rhythm (<I>n</I> = 8). Four of the eight dogs and an additional four dogs were paced into persistent AF. Carvedilol reduced heart rate [from 103 b.p.m. (95% confidence interval (CI), 100–105) to 100 b.p.m. (95% CI, 98–102), <I>P</I> = 0.044], suppressed integrated nerve activities (Int-NAs, SGNA by 17%, VNA by 19%, and SLGPNA by 12%; all <I>P</I> < 0.05 vs. the baseline), and significantly reduced the incidence (from 8 ± 6 to 3 ± 3 episodes/day, <I>P</I> < 0.05) and total duration (from 68 ± 64 to 16 ± 21 s/day, <I>P</I> < 0.05) of paroxysmal atrial tachycardia (PAT). Following the development of persistent AF, carvedilol loading was associated with AF termination in three dogs. In the remaining five dogs, Int-NAs were not significantly suppressed by carvedilol, but SGNA significantly increased by 16% after carvedilol withdrawal (<I>P</I> < 0.001).</P><P><B>Conclusion</B></P><P>Carvedilol suppresses ANA and PAT in ambulatory dogs during sinus rhythm.</P>
Choi, Eue-Keun,Kim, Hyo-Soo,Park, Kyung-Woo,Kim, Hyung-Kwan,Cho, Joung-Won,Lee, Myoung-Mook,Park, Young-Bae,Choi, Yun-Shik Japanese Circulation Society. 2005 CIRCULATION JOURNAL Vol.69 No.7
<P><B>Background</B> There is a paucity of information regarding the impact of the coronary collaterals on prognosis in type 2 diabetic (T2DM) patients. We developed a novel index, which considers not only the degree of collateral circulation but also the stimulus of collateral development, and investigated its prognostic value in T2DM patients with coronary artery disease (CAD). <B>Methods and Results</B> One hundred and ninety four consecutive T2DM patients were analyzed and followed for an average of 30 months. We measured the diameter stenosis (DS; %), corrected TIMI frame count (CTFC) and Rentrop score at 3 major epicardial coronary arteries. The collateral development (CD) score was calculated by: (Σ Rentrop score +1)/Σ [DS (%) × CTFC] ×1,000. During the follow-up, acute cardiovascular events occurred in 49 patients. By multivariate analysis, the CD score was an independent predictor of adverse events not only in the total population (p<0.001), but in all 3 subgroups (p=0.020 for coronary artery bypass grafting, p=0.030 for percutaneous transluminal coronary angioplasty (PTCA) and p=0.003 for the medical group). Furthermore, patients in the tertile with the highest CD score showed improved survival by Kaplan-Meier analysis in the total population, the PTCA and the medical group. <B>Conclusions</B> The CD score, a novel index of collateral development, may be a useful predictor of clinical outcome in T2DM patients with CAD. (<I>Circ J</I> 2005; <B>69:</B> 786 - 792)</P>
Cardiovascular Research Using the Korean National Health Information Database
Eue-Keun Choi 대한심장학회 2020 Korean Circulation Journal Vol.50 No.9
The Korean National Health Information Database (NHID) contains nationwide claims data, including sociodemographic data, health care utilization, health screening data, and healthcare provider information. To compensate for the limitations of randomized clinical trials, real-world observational studies using claims data have emerged as a novel research tool. We summarized the structure of the Korean NHID and the recent researches conducted in the field of cardiovascular science. Epidemiological studies, prescription patterns, temporal trends, comparison of effectiveness and safety of treatments, variability index using laboratory data, and rare intractable disease constitute interesting topics of research in cardiovascular science using the NHID. The operational definition of covariates and clinical outcomes is important for researchers interested in using the NHID data as new tools to prove their hypothesis. A step-by-step approach adopted by a team of data scientists, epidemiologists, statisticians, and clinical researchers may be most effective while designing research studies. The ultimate direction of research using the NHID should aim to improve the welfare of the public by promoting public health, reducing medical costs, and guiding healthcare policies.
Choi, You-Jung,Choi, Eue-Keun,Han, Kyung-Do,Jung, Jin-Hyung,Park, Jiesuck,Lee, Euijae,Choe, Wonseok,Lee, So-Ryoung,Cha, Myung-Jin,Lim, Woo-Hyun,Oh, Seil Elsevier 2018 INTERNATIONAL JOURNAL OF CARDIOLOGY Vol.273 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Atrial fibrillation (AF) and stroke are common in hypertrophic cardiomyopathy (HCM). We aimed to determine the prevalence and incidence of AF and stroke in patients with HCM during a 10-year period.</P> <P><B>Methods</B></P> <P>Using the Korean National Health Insurance Services database, we identified patients diagnosed with HCM from the entire Korean population between 2005 and 2015. The annual prevalence and incidence of AF and stroke in HCM patients were estimated.</P> <P><B>Results</B></P> <P>The prevalence of AF in HCM patients has gradually increased to 1.6-fold from 13.4% in 2005 to 20.9% in 2015. The incidence of AF ranged from 4.1 to 5.5%, a similar trend was observed for each year in HCM patients. The prevalence of stroke in HCM patients was approximately 10%, while that in HCM patients with AF was about 20%. During 8741 person-years, AF-related stroke occurred in 257 subjects among 2309 HCM patients with new-onset AF. The overall incidence rate of AF-associated stroke was 2.94 per 100 person-years. In subgroup analysis, the incidence rate of AF-associated stroke was 1.49 per 100 person-years in the under 45 year-old group and 1.48 per 100 person-years in the group with CHA<SUB>2</SUB>DS<SUB>2</SUB>VASc score of 0 or 1 point in HCM patients.</P> <P><B>Conclusions</B></P> <P>The prevalence of AF in HCM patients gradually increased over 10 years. The annual risk of AF-associated stroke in HCM was over 1% even in younger patients and those with CHA<SUB>2</SUB>DS<SUB>2</SUB>VASc score of 0 or 1 point, which provide evidence to support the prevention of stroke in HCM patients with AF.</P> <P><B>Highlights</B></P> <P> <UL> <LI> This is the first largest nationwide study on hypertrophic cardiomyopathy (HCM), a rare myocardial disease in Korea. </LI> <LI> The prevalence of AF in HCM patients gradually increases to 1.6-fold from 13.4% in 2005 to 20.9% in 2015. </LI> <LI> The annual incidence of AF in HMC patients was about 5%, and higher in female and the elderly. </LI> <LI> The prevalence of stroke in HCM patients with AF was about 20%, which were more than twice that in overall HCM patients. </LI> <LI> The risk of AF-related stroke in HCM patients was >1% per person-year even in younger patients or low CHA<SUB>2</SUB>DS<SUB>2</SUB>VAS<SUB>C</SUB> score. </LI> </UL> </P>
Oh, Seil,Choi, Eue-Keun,Zhang, Youhua,Mazgalev, Todor N. Ovid Technologies Wolters Kluwer -American Heart A 2011 Circulation. Arrhythmia and electrophysiology Vol.4 No.4
<P>Autonomic denervation may suppress atrial fibrillation (AF) vulnerability. This study was designed to assess the short- to mid-term effects of botulinum toxin, a cholinergic neurotransmission blocker, on AF inducibility.</P>
Atrial fibrillation risk in metabolically healthy obesity: A nationwide population-based study
Lee, HyunJung,Choi, Eue-Keun,Lee, Seung-Hwan,Han, Kyung-Do,Rhee, Tae-Min,Park, Chan-Soon,Lee, So-Ryoung,Choe, Won-Seok,Lim, Woo-Hyun,Kang, Si-Hyuck,Cha, Myung-Jin,Oh, Seil Elsevier/North-Holland Biomedical Press 2017 International journal of cardiology Vol.240 No.-
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>Metabolically healthy obese (MHO) individuals are reported to have a marginal increase in cardiovascular risk; however, their atrial fibrillation (AF) risk is unclear. We aimed to assess AF risk in MHO individuals and identify whether AF development is associated with obesity or influenced by metabolic comorbidities.</P> <P><B>Methods</B></P> <P>A retrospective cohort of 389,321 individuals (age, 45.6±14.5years; male, 52.1%) was extracted from the Korean National Health Insurance sample database between 2004 and 2006 and followed-up for new-onset AF until 2013. Subjects with diabetes mellitus, hypertension, and/or dyslipidemia were classified as “metabolically unhealthy.” The cohort was stratified into four groups according to obesity and metabolic healthiness: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), MHO, and metabolically unhealthy obese (MUO).</P> <P><B>Results</B></P> <P>AF was newly diagnosed in 5106 (1.3%) individuals during a mean follow-up of 7.5±1.5years. The AF incidence rates for the MHNO, MUNO, MHO, and MUO groups were 0.76, 2.66, 1.10, and 2.88 per 1000 person-years, respectively. Compared with the MHNO group, the MHO group had increased AF risk (adjusted hazard ratio, 1.30; 95% CI, 1.14–1.48) on multivariate analysis. One fourth of the MHO cohort became metabolically unhealthy, contributing to increased AF risk. Obesity was an independent risk factor for AF, and increased AF risk by 20%. Metabolic unhealthiness increased AF risk by around 40%, and of its components, hypertension contributed the most.</P> <P><B>Conclusions</B></P> <P>MHO individuals are at increased risk for AF development, and obesity was independently associated with elevated AF risk.</P>